Today at 11:21 AM
Merck's blood vessel disease drug passes final stage of testing
Merck & Co's $11.5 billion acquisition of pharmaceutical company Acceleron Pharma last year enabled Merck & Co to take advantage of therapy that achieved a major late-stage study goal in patients with advanced blood vessel disorder, Merck said on Monday.
Truist Securities analyst Robin Karnauskas said that in addition to the fact that the data obtained during testing confirm the correctness of the Acceleron deal, trial data also support Merck's promising cardiovascular drug line.
By 2030, Merck's cardiovascular product line is expected to consist of 8 approved drugs and reach a peak in sales of $10 billion, the company said.
Recommended
China to increase oil imports to replenish strategic reserves — Energy Aspects
Today at 11:26 AM
Today at 11:21 AM
Ethereum surpassed $3,000 amid reduced exchange supply
Today at 11:08 AM
Today at 10:43 AM
Bitcoin surges past $123,000 level on Monday
Today at 10:24 AM
Top news
Today at 10:43 AM
Today at 10:20 AM
Today at 9:58 AM
Today at 9:44 AM